Skip to main content
. 2022 Jun 3;46(5):701–712. doi: 10.4093/dmj.2022.0002

Fig. 3.

Fig. 3.

Annual initiation rate of sodium-glucose cotransporter 2 inhibitor (SGLT2i) within a year after the first hospitalization for (A) atherosclerotic cardiovascular disease (ASCVD) or (B) heart failure (HF).